Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Jeong Han Seo"'
Autor:
Junyoung Shin, Baknoon Ham, Jeong-Han Seo, Sae Byul Lee, In Ah Park, Gyungyub Gong, Sung-Bae Kim, Hee Jin Lee
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Despite the introduction of trastuzumab, pathologic complete response (pCR) is not attained in approximately 30–40% of Human epithelial growth factor receptor-2-positive breast cancer. Tumor-infiltrating lymphocytes (TIL) have been sugg
Externí odkaz:
https://doaj.org/article/24635ec77265460c93c16096eb303ca4
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Triple-Negative Breast Cancer (TNBC) is an aggressive and complex subtype of breast cancer. The current biomarkers used in the context of breast cancer treatment are highly dependent on the targeting of oestrogen receptor, progest
Externí odkaz:
https://doaj.org/article/bbec38a12bd548308551a4c357926361
Autor:
Miseon Lee, Jeong-Han Seo, Sungjae Song, In Hye Song, Su Yeon Kim, Young-Ae Kim, Gyungyub Gong, Jeong Eun Kim, Hee Jin Lee
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundHigh-precision human leukocyte antigen (HLA) genotyping is crucial for anti-cancer immunotherapy, but existing tools predicting HLA genotypes using next-generation sequencing (NGS) data are insufficiently accurate.Materials and MethodsWe co
Externí odkaz:
https://doaj.org/article/b82fe310d48140da8396525a1657a637
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0271ecfe8a07292e98457ba61fb91d2e
https://doi.org/10.1136/jitc-2022-sitc2022.1034
https://doi.org/10.1136/jitc-2022-sitc2022.1034
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d037bb8348c92d6e5806158bcdcff9a3
https://doi.org/10.1136/jitc-2022-sitc2022.1055
https://doi.org/10.1136/jitc-2022-sitc2022.1055
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
BMC Cancer
BMC Cancer
Background Triple-Negative Breast Cancer (TNBC) is an aggressive and complex subtype of breast cancer. The current biomarkers used in the context of breast cancer treatment are highly dependent on the targeting of oestrogen receptor, progesterone rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6da0fb89c8f965e323d38427d939582
http://link.springer.com/article/10.1186/s12885-020-07399-8
http://link.springer.com/article/10.1186/s12885-020-07399-8
Autor:
Gyungyub Gong, Hee Jin Lee, Sun-Hee Heo, Heejae Lee, In Ah Park, Hajar Rajaei, Hyeonjin Lee, Young-Ae Kim, In Hye Song, Jeong-Han Seo
Publikováno v:
Immunologic Research. 68:233-245
A higher level of tumor-infiltrating lymphocytes (TILs) is associated with better prognosis in breast cancer patients. Adoptive transfer of lymphocytes coupled with conventional therapies has appealed to many clinicians and investigators as an effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffa0cb9ef59ba0cac65a7b0d4f5efb08
https://doi.org/10.1007/s12026-020-09150-8
https://doi.org/10.1007/s12026-020-09150-8
Autor:
Hye Seon Park, Gyungyub Gong, Hee Jin Lee, Heejae Lee, Young-Ae Kim, Young Ho Kim, Jeong-Han Seo, Hyun Lee
Publikováno v:
Cancer Immunology, Immunotherapy. 69:2381-2391
The clinical significance of adoptive tumor-infiltrating lymphocyte (TIL) therapy has been demonstrated in many clinical trials. We analyzed the in vitro reactivity of cultured TILs against autologous breast cancer cells. TILs and cancer cells were c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::150ca9956ab23829ae6cbca6c8979945
https://doi.org/10.1007/s00262-020-02633-5
https://doi.org/10.1007/s00262-020-02633-5
Autor:
Sei-Hyun Ahn, Hee Jeong Kim, Sung Wook Jung, Sun-Hee Heo, Yeon ho Choi, Young Jin Cho, In Hye Song, Hye Seon Park, Won Seon Bang, Gyungyub Gong, Young-Ae Kim, Hee Jin Lee, Heejae Lee, Jeong-Han Seo
Publikováno v:
Cancer research and treatment. 54(4)
Background: The expression of major histocompatibility complex class I (MHC I) has previously been reported to be negatively associated with estrogen receptor (ER) expression. Furthermore, the expression of MHC I, the level of tumor-infiltrating lymp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14067be8602c2695783638f50f381661
https://pubmed.ncbi.nlm.nih.gov/34942685
https://pubmed.ncbi.nlm.nih.gov/34942685
Autor:
In Hye Song, Young-Ae Kim, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, Yeon ho Choi, Heejae Lee, Jeong-Han Seo, Youngjin Cho, Sung Wook Jung, Hee Jeong Kim, Sei Hyun Ahn, Hee Jin Lee, Gyungyub Gong
Publikováno v:
Cancer Research & Treatment; Oct2022, Vol. 54 Issue 4, p1111-1120, 10p